To provide a high and stable income, with the prospect of capital and income growth over the long term.This Fund is made up of around 70% UK equities and 30% UK investment grade bonds, A and AA rated.
Name | % Net Assets |
---|---|
Royal Dutch Shell | 6.7% |
BP | 6.3% |
GlaxoSmithKline | 4.1% |
HSBC | 3.8% |
AstraZeneca | 3.6% |
Vodafone | 3.0% |
British American Tobacco | 2.9% |
Unilever | 2.4% |
BHP Billiton | 2.3% |
BG Group | 1.7% |
Key | % Net Assets |
---|---|
Royal Dutch Shell | 6.7% |
BP | 6.3% |
GlaxoSmithKline | 4.1% |
HSBC | 3.8% |
Other | 79.1% |
Date | 15-Dec-2017 |
---|---|
NAV | 167.10p |
Currency | GBP |
Change | -0.20p |
% | -0.12% |
YTD change | 167.10p |
YTD % | n/a |
Fund Inception | 01/10/1994 |
---|---|
Fund Manager | Jamie Streeter / James Illsley / Talib Sheikh |
TER | 1.68 (31-Jan-2013) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | £100 |
Savings | £100 |
Charges | |
---|---|
Initial | 3.50% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.07 |
You are here: research